Tim Smith

These data, given sustainability targets in healthcare, may be considered by clinicians and by patients discussing DPIs.

The THESEUS study was conducted to look at current HS management and the influences on treatment decisions, with the goal of informing future randomized controlled trials.

These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.

These data indicate a significant ability of this treatment to address patients’ psoriatic symptoms in a comprehensive manner, despite varying characteristics and demographics.

In this analysis, the investigators note that the clinical association may be helpful to be taken into account as clinicians treat patients with HS.

These data indicate the necessity of further research to clarify any associations between COVID-19 infection, the virus’s associated vaccines, and progression of vitiligo.

This research had been conducted to look into prior studies linking daily pollen counts to respiratory allergic health outcomes.

These phase 2 data on hidradenitis suppurativa patients highlight new information on the use of lutikizumab as a treatment alternative.

These findings highlight the real access barriers faced by TGD individuals as well as the necessity of additional research to promote evidence-based hormonal acne treatments.

These findings may require further evaluation using classification of age range as well as severity of disease, allowing for more precise results.

The FDA decision on berdazimer gel, 10.3%, represents the second approved treatment for the viral-borne skin disease.

These data on PMF among coal miners suggest that urgent action may need to be taken to protect these workers from the preventable disease.

Despite these findings, the study highlights the need for a careful decision on the use of lung biopsy in older children given both benefits and risks.

The December 2023 month in review for dermatology covers major stories regarding a new FDA approval, several new treatment findings, and news on attitudes toward those with acne.

Twice-daily PDE4-inhibition using 10–40 mg of orismilast showed promise though further studies may be necessary to validate these findings.

These data expand upon the limited literature available around the world regarding this inflammatory skin disorder.

These study results highlight the necessity of raising awareness and implementing public health interventions designed to address respiratory health among this and other populations in early childhood.

This research expanded upon existing knowledge from pediatric pulmonary providers regarding wildfire smoke risks and prevention.

These data on ixekizumab in real-world settings shed light on drug survival information for both those with psoriasis and those with psoriatic arthritis.

These results provided valuable insights into occupational anaphylaxis through the use of anaphylaxis registry data.

This study looked at results of DOC, allergy risk level risk distinctions, and rationale for families and physicians to move forward with DOC.

This literature review highlights several of the processes and factors related to the stratum corneum and sensitive, dry, or flaky skin in adults.

These new data highlight the importance of larger trials to evaluate the persistence of this treatment’s efficacy and safety seen here.

This research letter highlights opportunities for researchers to develop more innovative treatments for skin disease, especially for conditions that have unmet therapeutic needs.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

The FDA’s approval of Chiesi Global Rare Diseases’ topical gel marks the first approval for the variant of EB known as JEB.

Addressing a lack of quantitative data on AID, this study used validated measures in a real-world setting to corroborate the psychosocial benefits seen in prior qualitative research.

While the ACT program did not benefit patients in the study’s primary outcome measure, it did lead to some other benefits for those with type 1 diabetes.

The decision by the FDA is a step closer to omalizumab’s potential approval, making it the potential first medicine to reduce reactions to many different food allergens after accidental exposure.

These newly-updated parameters were a response by the ACAAI and the AAAAI to recent evidence that had become visible.